Brief: Braxia Scientific Awarded Government Of Canada Funding To Complete First Of Its Kind Ketamine Clinical Trial For Bipolar Depression
17/06/2021 12:40
June 17 (Reuters) - Braxia Scientific Corp BRAX.CD :
* BRAXIA SCIENTIFIC AWARDED GOVERNMENT OF CANADA FUNDING TO
COMPLETE FIRST OF ITS KIND KETAMINE CLINICAL TRIAL FOR BIPOLAR
DEPRESSION
Source text for Eikon: ID:nCNW3JJZxa
Further company coverage: BRAX.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Braxia Scientific
See all newsBrief: Braxia Scientific Reports Q3 2022 Financial Results
Brief: Braxia Scientific CEO Roger Mcintyre To Join Advisory Board Of At-Home Telemedicine Platform KetaMD
Brief: Braxia Scientific To Commence Canada's First Multiple-Dose Psilocybin Trial For Treatment Resistant Depression
Brief: Braxia Scientific Launches Psilocybin-Assisted Clinical Therapy Training Program
Brief: Braxia Scientific Awarded Government Of Canada Funding To Complete First Of Its Kind Ketamine Clinical Trial For Bipolar Depression